Top

Published in:

01-01-2012 | Clinical Study – Patient Study

Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma

Authors: Lola B. Chambless, Scott L. Parker, Laila Hassam-Malani, Matthew J. McGirt, Reid C. Thompson

Published in: Journal of Neuro-Oncology | Issue 2/2012

Abstract

Type 2 diabetes mellitus (DM) and obesity are known risk factors for poor outcomes in patients with systemic malignancies but are not well-studied in the brain tumor population. In this study we asked if type 2 DM and elevated body mass index (BMI) are independent risk factors for poor prognosis in patients with high-grade glioma (HGG.). We conducted a retrospective cohort study of 171 patients surgically treated for HGG at a single institution. BMI and records of pre-existing type 2 DM were obtained from medical histories. Variables associated with survival in a univariate analysis were included in the multivariate Cox model if P < 0.10. Variables with probability values >0.05 were then removed from the multivariate model in a step-wise fashion. Mean age at diagnosis was 55.0 ± 17.3 years. Fifteen (8.8%) patients had a history of type 2 DM. Fifty-eight (35.8%) patients had a BMI < 25, 55 (34.0%) BMI 25–30, and 49(30.2%) BMI > 30. Radiation therapy, temozolomide, and higher KPS score were independently associated with prolonged survival while increasing age was associated with decreased survival. DM (P = 0.001) and increasing BMI (P = 0.003) were found to be independently associated with decreased survival. Diabetics had a decreased median overall survival (312 vs. 470 days, P = 0.003) and PFS (106 vs. 166 days, P = 0.04) compared to non-diabetics. Increasing BMI (<25, 25–30, and >30) was also associated with decreased median PFS: 195 vs. 165 vs. 143 days, respectively. Pre-existing DM and elevated BMI are independent risk factors for poor outcome in patients with HGG.

Central Brain Tumor Registry of the United States (2011) CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2004–2007

Tait MJ, Petrik V, Loosemore A, Bell BA, Papadopoulos MC (2007) Survival of patients with glioblastoma multiform has not improved between 1993 and 2004: analysis of 625 cases. Br J Neurosurg 21:496–500PubMedCrossRef

Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10–14PubMedCrossRef

Burger PC, Green SB (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59:1617–1625PubMedCrossRef

Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 6:227–235PubMedCrossRef

Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A et al (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J Neurosurg 99:467–473PubMedCrossRef

Perry A, Jenkins R, O’Fallon JR et al (1999) Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and P53 expression. Cancer 86:672–683PubMedCrossRef

Tortosa A, Vinolas N, Villa S et al (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97:1063–1071PubMedCrossRef

Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA (2009) Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 27:1082–1086PubMedCrossRef

10.

McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, Olivi A, Quinones-Hinojosa A (2008) Persistent outpatient hyperglycemia is independently associate with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 62:286–289CrossRef

11.

El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380PubMedCrossRef

12.

Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365–1374PubMedCrossRef

13.

Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type 2 diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083PubMedCrossRef

14.

Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef

15.

Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colon cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef

16.

Mitri J, Castillo J, Pittas AG (2008) Diabetes and risk of non-hodgkins lymphoma: a metaanalysis of observational studies. Diabetes Care 31:2391–2397PubMedCrossRef

17.

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591PubMedCrossRef

18.

Calle EE, Rodriquez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. NEJM 348:1625–1638PubMedCrossRef

19.

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578PubMedCrossRef

20.

Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL (2008) Long-term all-cause mortality in cancer patients with pre-existing diabetes mellitus. JAMA 300:2754–2764PubMedCrossRef

21.

Haydon AM, Macinnis RJ, English DR, Giles GG (2006) Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55:62–67PubMedCrossRef

22.

Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study Collaborators (2008) Lifestyle factors and primary glioma and meningioma tumors in the million women study cohort. Br J Cancer 99:185–190PubMedCrossRef

23.

Moore SC, Rajaraman P, Dubrow R et al (2009) Height, body mass index, and physical activity in relation to glioma risk. Cancer Res 69:8349–8355PubMedCrossRef

24.

Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586–623PubMedCrossRef

25.

Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD (2007) Insulin-like growth factor type 1 biology and targeting in malignant gliomas. Neuroscience 145:795–811PubMedCrossRef

26.

Wang H, Wang H, Shen W et al (2003) Insulin-like growth factor-binding protein 2 enhances GBM invasion by activating invasion-enhancing genes. Cancer Res 63:4315–4321PubMed

27.

Lammers R, Gray A, Schlessinger J, Ulrich A (1989) Differential signalling potential of insulin and IGF-1 receptor cytoplasmic domains. EMBO J 8:1369–1375PubMed

28.

Hirano H, Lopes MB, Laws ER et al (1999) Insulin-like growth factor 1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro Oncol 1:109–119PubMed

29.

Zumkeller W, Westphal M (2011) The IGF/IGFBP system in CNS malignancy. Mol Pathol 54:227–229

30.

McDonald KL, O’Sullivan MG, Parkinson JF et al (2007) IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 66:405–417PubMedCrossRef

31.

Sallinen SL, Sallinen PK, Haapasalo HK et al (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60:6617–6622PubMed

32.

Santosh V, Arivazhagan A, Sreekanthreddy P et al (2010) Grade-specific expression of insulin-like growth factor-binding proteins 2, 3 and 5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev 19:1399–1408PubMedCrossRef

33.

Wang H, Fuller GN, Zhang W (2004) Insulin-like growth factors and insulin-like growth factors binding proteins in CNS tumors. In: Zhang W, Fuller GN (eds) Genomic and molecular neurooncology. Jones and Bartlett, Sudbury, pp 119–130

34.

Gariboldi MB, Ravizza R, Monti E (2010) The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 80:455–462PubMedCrossRef

35.

Pozsgai E, Schally AV, Halmos G, Rick F, Bellyei S (2010) The inhibitory effect of a novel cytotoxic somatostatin analog AN-162 on experimental glioblastoma. Horm Metab Res 42:781–863PubMedCrossRef

36.

Yin S, Girnita A, Stromberg T, Khan Z, Andersson S, Zheng H, Ericsson C, Axelson M, Nister M, Larsson O, Ekstrom TJ, Girnita L (2010) Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 12:19–27PubMedCrossRef

37.

Jones LW, Ali-Osman F, Lipp E, Marcello JE, McCarthy B, McCoy L, Rice T, Wrensch M, Il’yasova D (2010) Association between body mass index and mortality in patients with glioblastoma multiforme. Cancer Causes Control 21:2195–2201PubMedCrossRef

38.

Shields M, Carroll MD, Ogden CL (2011) Adult obesity prevalence in Canada and the United States. NCHS Data Brief, Centers for Disease Control

39.

Dube JJ, Amati F, Toledo FG, Stefanovic-Racic M, Rossi A, Coen P, Goodpaster BH (2011) Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol, and ceramide. Diabetologia 5:1147–1156CrossRef

40.

Kourelis TV, Siegel RD (2011) Metformin and cancer: new applications for an old drug. Med Oncol. doi:10.1007/s12032-011-9846-7

41.

Micic D, Cvijovic G, Trajkovic V, Duntas LH, Polovina S (2011) Metformin: its emerging role in oncology. Hormones 10:5–15PubMed

42.

Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese representative population prospective cohort study of 800, 000 individuals. BMC Cancer 11:20PubMedCrossRef

Title: Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma
Authors: Lola B. Chambless
Scott L. Parker
Laila Hassam-Malani
Matthew J. McGirt
Reid C. Thompson
Publication date: 01-01-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0676-4

At a glance: The STEP trials

Springer Medicine

Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

Novel approaches to treating leptomeningeal metastases

Germinoma occurring 2 years after total resection of an intracranial epidermoid cyst in the pineal region

Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience

Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment